drugset
drugset / Trial / NCT04194931

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

NCT04194931 ↗

Phase 1 Unknown 20 enrolled The First Affiliated Hospital of Nanchang University
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, open-label, single center study to evaluate the safety and efficacy of BCMA/CD19 CAR-T cells in patients with BCMA+，CD19+ relapsed or refractory multiple myeloma.

Timeline

Start
2019-12-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BCMA CAR-T cells Cell therapy 1e+06 cells/kg —
Subject BCMA CAR-T cells Cell therapy 5e+06 cells/kg —
Subject CD19 CAR-T cells Cell therapy 1e+06 cells/kg —
Subject CD19 CAR-T cells Cell therapy 5e+06 cells/kg —

Indications

refractory plasma cell neoplasm